Oral Wegovy and Poundayo: 25–50% Cheaper Than Injectables with Differences in Efficacy

In the recently globally spotlighted obesity treatment market, products in the form of 'oral medicine' rather than injectables are appearing and gathering great expectations. According to a video from the YouTube channel 'A Pharmacist's Story About Medicine', through the content 'A Thorough Comparison and Summary of Oral Wegovy (Wegovy Pill) and Poundayo', it is explained that while oral products have the advantage of being more convenient to take and cheaper in price compared to existing injectables, they show distinct differences in ingredients and administration methods.

Differences in Ingredients and Administration: Mandatory Fasting vs. Food Irrelevant

Both drugs act as GLP-1 hormone analogs that induce a feeling of satiety, but their fundamental ingredient compositions are different. Oral Wegovy is a protein (peptide)-based hormone analog with the same 'semaglutide' ingredient as the injectable. On the other hand, Poundayo is an organic compound ingredient called 'orforglipron'.

This difference in ingredients leads to differences in administration methods. Because there is a risk that the protein ingredient in oral Wegovy could be decomposed by gastric acid or food, the principle is 'fasting administration' so that it adheres well to the stomach wall. In the video, it is advised that when taking oral Wegovy, 'you should only drink water less than approximately one hundred milliliters', explaining that if too much water is consumed, it may not adhere properly to the stomach wall, leading to a decrease in absorption rates. Additionally, the instruction 'maintain a fast for thirty minutes after taking it' follows.

On the other hand, since Poundayo is a drug that is not a protein ingredient, it features the characteristic of being able to be taken relatively freely regardless of food intake or the amount of water. However, since Poundayo is metabolized in the liver, caution must be taken regarding interactions with other drugs.

Weight Loss Efficacy and Price Comparison: Advantage of Wegovy Pill

Looking at the weight loss efficacy based on clinical data, oral Wegovy was shown to have a slightly higher efficiency in numerical terms than Poundayo. According to the data cited in the video, oral Wegovy had a 'weight loss effect of about fourteen percent' when taken for 15 months, while Poundayo showed a weight loss effect of about 11–12% when taken for 17 months. This suggests that both drugs are much safer and more effective than existing psychotropic diet drugs. In particular, according to meta-analysis data announced in 2026, the injectable Mounjaro showed the highest weight loss effect at about 15%, followed by oral Wegovy.

In terms of price, the merit of oral products is clear. Based on local standards in the United States, oral products were shown to be 'approximately twenty-five to fifty percent cheaper than injectables'. Based on a one-month supply, oral Wegovy and Poundayo form a price range between approximately 150 dollars and 300 dollars, projecting that more economical management will be possible compared to injectables. This means that when choosing a low dose, the monthly medicine cost is at the level of approximately 200 dollars (about 200,000 won), and benefits such as blood sugar control, lowering inflammation levels, and reducing the risk of hypertension, hyperlipidemia, and dementia can be expected along with weight management.

Side Effects and Drug Interactions to Watch Out For

Both drugs commonly can cause gastrointestinal side effects such as nausea, diarrhea, vomiting, constipation, and indigestion, and there is also the possibility of hair loss due to nutritional deficiency. Furthermore, depending on mouse experiment results, caution is required for the possibility of thyroid medullary cancer occurrence, or pancreatitis, gallbladder/biliary tract diseases, acute kidney disease due to water deficiency, and retinal occlusive eye diseases. In particular, since lean body mass (such as muscle mass) can decrease by about 15% during the weight loss process, consistent strength training, protein intake, and sufficient water supply must be accompanied.

Especially when taking Poundayo, drug interactions related to liver enzyme metabolism must be checked. For patients taking 'simvastatin' among hyperlipidemia drugs, if they combine it with Poundayo, 'in the case of simvastatin, the concentration in the plasma can increase by up to 2.5 times', so they must consult with their primary physician. Besides this, interactions with clarithromycin (antibiotic), carbamazepine (anticonvulsant), cyclosporine (immunosuppressant), verapamil (antiarrhythmic), and modafinil (stimulant) have been reported.

Also, it can affect gastrointestinal motility and interfere with the absorption of contraceptives. In the video, it is advised that 'since contraceptives can also be affected by gastrointestinal motility and thus their absorption can be affected', when starting the medicine or increasing the dose, 'you should just use additional contraception for about thirty-one days while taking the medicine'. In the case of South Korea, Poundayo is in a situation where its release can be expected in the first half of next year. Obesity treatment should be decided after consulting with an expert according to medical standards, such as being BMI 30 or higher or BMI 28 or higher accompanied by adult diseases.